Julian Krick

ENLYZE offers a combined hard- and software solution to enable industrial companies in optimizing the quality and profitability of their manufacturing. Through extraction of machine- and production data and their processing and visualization in our web-based tool we help our clients minimize scrap, reach optimal machine utilization as well as implement predictive maintenance.

Welcome to Semalytix! Semalytix, the trailblazer in AI-driven innovations, empowers pharmaceutical companies to embrace a patient-centric approach like never before. With their revolutionary Pharos platform, fuelled by state-of-the-art AI and LLM technology, Semalytix undertakes the colossal task of consuming and analysing millions of forum posts, social media discussions, and CRM system records in the blink of an eye. Pharos becomes the conduit for capturing and harnessing the pulse of real-world perceptions and experiences shared by both healthcare practitioners and patients in the here and now. Through its captivating living reports, Pharos bestows invaluable insights upon pharmaceutical giants, guiding them to laser-focus on their customers genuine needs. It unlocks the profound understanding of what truly holds the potential to enhance their well-being, transforming lives in ways previously unimagined. Founded in 2015, Semalytix has grown to a team size of 75 employees and has executed more than 40 projects with the pharmaceutical industry with a total volume of EUR 3.8M between 2015 – 2019.

ENLYZE offers a combined hard- and software solution to enable industrial companies in optimizing the quality and profitability of their manufacturing. Through extraction of machine- and production data and their processing and visualization in our web-based tool we help our clients minimize scrap, reach optimal machine utilization as well as implement predictive maintenance.

Welcome to Semalytix! Semalytix, the trailblazer in AI-driven innovations, empowers pharmaceutical companies to embrace a patient-centric approach like never before. With their revolutionary Pharos platform, fuelled by state-of-the-art AI and LLM technology, Semalytix undertakes the colossal task of consuming and analysing millions of forum posts, social media discussions, and CRM system records in the blink of an eye. Pharos becomes the conduit for capturing and harnessing the pulse of real-world perceptions and experiences shared by both healthcare practitioners and patients in the here and now. Through its captivating living reports, Pharos bestows invaluable insights upon pharmaceutical giants, guiding them to laser-focus on their customers genuine needs. It unlocks the profound understanding of what truly holds the potential to enhance their well-being, transforming lives in ways previously unimagined. Founded in 2015, Semalytix has grown to a team size of 75 employees and has executed more than 40 projects with the pharmaceutical industry with a total volume of EUR 3.8M between 2015 – 2019.

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the Federal Republic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Gründerfonds Ruhr is a private venture capital fund driving innovation in the Ruhr area by investing in new technologies impacting a broad range of industries. We deploy the capital, the business expertise and the industry access from leading international corporations who share our goal of building Ruhr-based start-ups with transforming ideas. Our objective is to be the institutional investor of choice for founders and become a trusted partner with the resources to catapult young companies to their next stage of development and commercial success. Our long-term vision is to thereby boost entrepreneurial spirit in our region. Key sectors include chemicals & new materials, energy & industrial sector, life sciences & healthcare, logistics & retail and the digital economy. Our current portfolio consists of Abalos Therapeutics, DIMATE, Emergence Therapeutics, Fasciotens, Masterplan.com and talpasolutions. For further information: www.gruenderfonds-ruhr.com

OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research, thus having a real impact and enabling concrete solutions for different challenges facing society today. As an owner-managed venture capital investor with offices in Munich and Zug, OCCIDENT supports start-ups in the life sciences and industrial tech sectors from the seed stage onwards, accompanies their portfolio companies over the long term both financially as well as with their extensive experience, and thus enables founding teams to achieve outstanding results. With a strong entrepreneurial mindset, OCCIDENT invests its own money and makes decisions based on sustainable potential for success. Co-operation with the founding teams of their portfolio companies motivates the OCCIDEN team and inspires them every day. They are energized by their passion and drive, and the often very intense exchange spurs them on to tackle challenges together. OCCIDENT’s aim with each and every one of their investments is to make a positive contribution to society in a sustainable way.